SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
Globe Newswire•14/10/2026•08:37 ET
2
Key Highlights
- ➤Kevin Chung named 2026 recipient of the Combat Nephrology Award
- ➤QUELIMMUNE SAVE Registry reported 76% survival at Days 28 and 60
- ➤SAVE Registry observed no device-related adverse events or infections among 21 patients
- ➤NEUTRALIZE-AKI pivotal trial is evaluating SCD therapy in 339 adults
- ➤QUELIMMUNE received FDA Humanitarian Device Exemption approval in February 2024
Expert Statements
Kevin Chung, MD, Chief Medical Officer of SeaStar Medical Holding Corporation
“I would like to thank Dr. Jesús Hernández Vaquero and the conference organizers for this deeply humbling honor. During the over two decades of caring for critically ill combat casualties, I came to the sober realization that current standards of care are not enough. Supporting a failing organ is not the same as treating the destructive hyperinflammation behind it. Closing that gap, in AKI and beyond, must be one of our highest priorities as a nephrology critical care community, and I'm grateful for the colleagues working together to make it happen.”
Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support
Keynote presentation and award ceremony to occur at Update in Critical Care Nephrology 2026
Get started
Create a free account to read the full story.